HIV-1 Env fusion peptide nanoparticle carrier conjugates and their use

US12053519B2 · kind B2 · utility

Assignee

• The United States of America, as represented by the Secretary, Department of Health and Human Services · US

Inventors

• Peter Kwong · Washington, US
• Li Ou · Bethesda, US
• John Mascola · Rockville, US
• Baoshan Zhang · Bethesda, US
• Kai Xu · Bethesda, US
• Wing-Pui Kong · Germantown, US
• Yaroslav Tsybovsky · Jefferson, US
• Cara W. Chao · Bethesda, US
• Jeffrey Boyington · Clarksburg, US
• Yiran Wang · Nanhu, CN

Key dates

• Filing date: Sep 23, 2019
• Grant date: Aug 6, 2024
• Expiry date: Mar 21, 2041

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2795/18122
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Embodiments of immunogenic conjugates including the HIV-1 Env fusion peptide and methods of their use and production are disclosed. In several embodiments, the immunogenic conjugates can be used to generate an immune response to HIV-1 Env in a subject, for example, to treat or prevent an HIV-1 infection in the subject.